Skip to main content
TipRanks
Go Ultimate75% OFF

Cellectar Biosciences (CLRB) Stock Statistics & Valuation Metrics

1,453 Followers

Total Valuation

Cellectar Biosciences has a market cap or net worth of $9.24M. The enterprise value is $9.08M.

Market Cap
$9.24M
Enterprise Value
$9.08M

Share Statistics

Cellectar Biosciences has 10,039,183 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
10,039,183
Owned by Insiders
0.91%
Owned by Institutions
40.23%

Financial Efficiency

Cellectar Biosciences’s return on equity (ROE) is -2.20 and return on invested capital (ROIC) is -222.48%.

Return on Equity (ROE)
-2.20
Return on Assets (ROA)
-1.45
Return on Invested Capital (ROIC)
-222.48%
Return on Capital Employed (ROCE)
-2.25
Revenue Per Employee
0
Profits Per Employee
-1.98M
Employee Count
11
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Cellectar Biosciences is -0.26. Cellectar Biosciences’s PEG ratio is -0.00.

PE Ratio
-0.26
PS Ratio
0.00
PB Ratio
0.74
Price to FCF
-0.39
Price to Operating Cash Flow
-0.67
PEG Ratio
-0.00

Income Statement

In the last 12 months, Cellectar Biosciences had revenue of 0 and earned -21.79M in profits. Earnings per share was -8.35.

Revenue
0
Gross Profit
-213.60K
Operating Income
-22.98M
Pretax Income
-21.79M
Net Income
-21.79M
EBITDA
-21.58M
Earnings Per Share (EPS)
-8.35

Cash Flow

In the last 12 months, operating cash flow was -24.61M and capital expenditures -9,259, giving a free cash flow of -24.62M billion.

Operating Cash Flow
-24.61M
Free Cash Flow
-24.62M
Free Cash Flow per Share
-1.41

Dividends & Yields

Cellectar Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-269.42%
Earnings Yield
-162.64%

Stock Price Statistics

Beta
1.17
52-Week Price Change
-68.49%
50-Day Moving Average
1.63
200-Day Moving Average
2.51
Relative Strength Index (RSI)
26.34
Average Volume (3m)
96.60K

Important Dates

Cellectar Biosciences upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 10, 2026
Next Earnings Date
Mar 11, 2027
Ex-Dividend Date
―

Financial Position

Cellectar Biosciences as a current ratio of 2.96, with Debt / Equity ratio of 4.13%

Current Ratio
2.96
Quick Ratio
2.96
Debt to Market Cap
0.00
Net Debt to EBITDA
0.59
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Cellectar Biosciences has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Cellectar Biosciences EV to EBITDA ratio is 0.53, with an EV/FCF ratio of 0.57.

EV to Sales
0.00
EV to EBITDA
0.53
EV to Free Cash Flow
0.57
EV to Operating Cash Flow
0.57

Balance Sheet

Cellectar Biosciences has $24.58M in cash and marketable securities with $1.53M in debt, giving a net cash position of $23.05M billion.

Cash & Marketable Securities
$24.58M
Total Debt
$1.53M
Net Cash
$23.05M
Net Cash Per Share
$2.30
Tangible Book Value Per Share
$1.28

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Cellectar Biosciences is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$10.00
Price Target Upside
986.96% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
―
EPS Growth Forecast
66.06%

Scores

Smart Score
―
AI Score
46